4 completed, 2 terminated. 6 Phase 2, 2 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 6 | Completed 4, Terminated 2 |
| Phase 1 | 2 | Completed 2 |
Follow Farydak: new trials by email Literature Review of Farydak trials Research Report on Farydak
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Panobinostat, Carfilzomib, and Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma Carfilzomib, Chemosensitivity Assay, Dexamethasone - Recurrent Plasma Cell Myeloma, Refractory Plasma Cell Myeloma | Phase 2 | Terminated | University of Washington | 9 | 2018-02-08 | 2022-05-09 |
| A Trial Evaluating Efficacy & Safety of RVD +/- Panobinostat in Transplant Eligible, Newly Diagnosed Multiple Myeloma (NDMM) Revlimid, Velcade, dexamethasone - Multiple Myeloma | Phase 2 | Terminated | Novartis Pharmaceuticals | 6 | 2016-06-14 | 2018-07-24 |
| Reducing the Residual Reservoir of HIV-1 Infected Cells in Patients Receiving Antiretroviral Therapy Panobinostat, Pegylated Interferon-alpha2a - HIV Infection | Phase 1 / Phase 2 | Completed | Massachusetts General Hospital | 17 | 2016-05-01 | 2024-02-28 |
| Panobinostat/Bortezomib/Dexamethasone in Relapsed or Relapsed-and-refractory Multiple Myeloma Panobinostat Capsules, Bortezomib Injection, Dexamethasone tablets - Multiple Myeloma | Phase 2 | Completed | pharmaand GmbH | 248 | 2016-04-27 | 2024-07-12 |
| Panobinostat (LBH589): Acute Graft Versus Host Disease (aGVHD) Prevention Panobinostat, Sirolimus, Tacrolimus - Graft Versus Host Disease, GVHD | Phase 2 | Completed | H. Lee Moffitt Cancer Center and Research Institute | 42 | 2016-03-04 | 2021-07-21 |
| LBH589 and Bevacizumab in Patients With Recurrent High Grade Glioma LBH589, bevacizumab - Malignant Glioma | Phase 1 / Phase 2 | Completed | Patrick Y. Wen, MD | 51 | 2009-03-01 | 2017-03-14 |
Multiple Myeloma (3) · Glioma (1) · Graft vs Host Disease (1) · HIV Infections (1) · Hematologic Diseases (1) · Recurrence (1)
H. Lee Moffitt Cancer Center and Research Institute (1) · Massachusetts General Hospital (1) · Novartis Pharmaceuticals (1) · Patrick Y. Wen, MD (1) · University of Washington (1) · pharmaand GmbH (1)
United States (6) · Australia (1) · Belgium (1) · Brazil (1) · Canada (1) · Czechia (1) · France (1) · Germany (1) · Greece (1) · Hungary (1) · Italy (1) · Lebanon (1) · Netherlands (1) · Norway (1) · Poland (1)
Andrew Cowan (1) · Daniel R Kuritzkes, MD (1) · Lia Perez, M.D. (1) · Mathias Lichterfeld, MD, PhD (1) · Patrick Y. Wen, MD (1) · Rajesh T Gandhi, MD (1)
PMID 21984064, PMID 25572329, PMID 33301738, PMID 34242388, PMID 37189240
2015 (1), P30CA015704 (1)